瘤透B细胞:它们在瘤微环境中的双重机械作用
Demin Xue1, Shaozhen Hu2, Runchen Zheng1
1School of Chinese Classics, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|September 13, 2024
概括
瘤透B细胞 (TIL-Bs) 在瘤微环境 (TME) 中在癌症免疫中发挥复杂的作用. 了解这些双重的抗瘤和促瘤功能对于开发有效的瘤免疫治疗策略至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症研究 癌症研究
背景情况:
- 瘤的发展与免疫系统功能障碍有关.
- 瘤微环境 (TME) 对瘤免疫疗法至关重要.
- 最初的研究重点是TME内的T细胞.
研究的目的:
- 探索瘤透B细胞 (TIL-Bs) 的组成和生物特征.
- 调查TIL-Bs在TME中的双重作用 (抗瘤和前瘤).
- 为推进瘤免疫治疗提供新的见解和策略.
主要方法:
- 对瘤微环境 (TME) 组成的分析.
- 瘤透B细胞 (TIL-Bs) 的生物特征的表征.
- 研究TIL-Bs在瘤免疫中的多方面的作用.
主要成果:
- 瘤透B细胞 (TIL-Bs) 在TME中表现出不同的功能.
- 通过TIL-Bs调解的抗瘤和促瘤效应都被确定.
- 突出了TIL-Bs在瘤免疫中的复杂相互作用.
结论:
- TIL-Bs是瘤免疫的关键参与者,影响免疫治疗结果.
- 针对TIL-Bs为新型癌症治疗策略提供了一个有希望的途径.
- 对TIL-B生物学的进一步研究可以改进瘤免疫治疗方法.
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
T Cell Types and Functions
961
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
961
B Cell Activation and Differentiation
1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Cell-mediated Immune Responses
67.8K
Overview
67.8K


